Table 4. Pharmacokinetics.
| Steady-state level (ng/mL) Cycle 1 (without binimetinib) |
Steady-state level (ng/mL) Cycle 2 (with binimetinib) |
||
|---|---|---|---|
| 5-FU | Pt#1 Pt#2 Pt#3 Pt#4 Pt#5 Pt#6 |
353.0 524.0 627.5 427.5 621.0 428.0 |
293.1 480.5 718.0 770.5 726.0 ND |
| Avg STD |
510.6 120.2 |
597.6 204.5 |
|
| Cmax (μg/L) | AUC (μg/L X hr) |
T1/2 (36) | Cmax (μg/L) | AUC (μg/L X hr) |
T1/2 (36) | ||
|---|---|---|---|---|---|---|---|
| Cycle 1 (without binimetinib) | Cycle 2 (with binimetinib) | ||||||
| Oxaliplatin | Pt#1 Pt#2 Pt#3 Pt#4 Pt#5 Pt#6 |
536.0 780.8 686.5 601.5 389.3 ND |
28618.0 31146.9 25757.7 18615.5 28764.2 ND |
56.7 32.7 30.6 27.0 38.3 ND |
ND 590.0 726.5 748.5 583.5 671.0 |
ND 51036.0 33953.4 25138.7 19805.3 31020.9 |
ND 77.9 38.9 26.4 26.3 24.7 |
| Avg STD |
598.8 148.9 |
26580.5 4844.8 |
37.1 11.7 |
663.9 75.9 |
32190.9 11861.2 |
38.8 22.6 |
|
5-FU, 5-flourouracil; ND, not determined; STD, standard deviation; Cmax, maximum serum concentration; AUC, area under the curve; T1/2, half-life.